|
| Press Releases |
|
 |
|
| Wednesday, June 1, 2016 |
|
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
| AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
| Wednesday, May 25, 2016 |
|
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
| Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
| Tuesday, May 24, 2016 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology. more info >> |
|
| Monday, May 16, 2016 |
|
|
U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. more info >> |
|
| Thursday, April 14, 2016 |
|
|
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies |
| Eisai Co., Ltd. announced today that its subsidiary in the Philippines, HI-Eisai Pharmaceutical Inc., has received approval for a new indication for the symptomatic treatment of dementia with Lewy bodies (DLB) for anti-Alzheimer's agent Aricept (donepezil hydrochloride) in the Philippines, and has commenced information provision activities. more info >> |
|
| Tuesday, April 5, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas. more info >> |
|
| Thursday, March 31, 2016 |
|
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
| Wednesday, March 30, 2016 |
|
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
| Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016. more info >> |
|
|
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options |
| Eisai Co., Ltd. ("the Company") today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 20:42 HKT/SGT
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities 
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 21, 2024 21:20 HKT/SGT
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 20:19 HKT/SGT
|
|
|
SGX-Listed Mooreast Appoints Norwegian Eirik Ellingsen as CEO to Drive Growth in Global Floating Offshore Wind Market
Nov 21, 2024 19:00 HKT/SGT
|
|
|
DesignInspire opens on December 5, with free admission for the public
Nov 21, 2024 17:54 HKT/SGT
|
|
|
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
|
|
|
Yahoo Finance Invest Asia 2024 - Disrupting Finance: Innovations Shaping The Future
Nov 21, 2024 14:14 HKT/SGT
|
|
|
TGL Presented by SoFi Names SYNLawn As Official Synthetic Surface Partner, Providing 31,000 Square Feet of Turf for SoFi Center's Tech-Infused Field of Play
Nov 21, 2024 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
